Skip to main content
Premium Trial:

Request an Annual Quote

CyVek Raises $5.5M in Preparation of Platform Launch

NEW YORK (GenomeWeb News) – CyVek today said that it has raised $5.5 million in a Series D financing round.

The funding will go toward building an infrastructure to commercialize the company's multiplex immunoassay technology called CyPlex, which uses a microfluidic cartridge for analyzing multiple biomarkers from small amounts of biological samples. CyPlex will be used initially for life sciences, drug discovery, and clinical research applications, the Wallingford, Conn.-based company said.

CyVek did not respond to a request for additional information about its commercialization plans.

Connecticut Innovations and private investors participated in the round, CyVek said.

"The funding provided by our investors will enable us to complete development-related activities and put together the team and infrastructure required to commercialize," Per Hellsund, founder, president and CEO of CyVek, said in a statement.

CyVek was founded in 2010 and raised $2 million in a private equity offering then. Last May, the firm raised $2 million in a Series C round.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.